Advanced lung cancer
Conditions
Interventions
The experimental group:Oral probiotic supplements
control group:Nil
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Pathologically confirmed non-small cell lung cancer, small cell lung cancer; 2.The clinical or pathological stages are stage IV and/or locally advanced where radical resection is not possible; 3.Driver gene mutation negative; Or targeted therapy failed to drive mutation-positive patients; 4.ICI (including PD1 inhibitor, PDL1 inhibitor, CTLA4 inhibitor, etc.) is intended to be treated; 5.The function of the main organs is basically normal; 6.Normal cognitive ability,and fully informed understanding.
Exclusion criteria
Exclusion criteria: 1.The expected survival is less than three months; 2.Symptoms of brain metastases are not under control; 3.Patients receiving radical treatment (including radical concurrent radiotherapy and chemotherapy, etc.); 4.Neoadjuvant therapy patients; 5.Patients with diseases of the immune system that require continuous treatment; 6.Past occurrence of grade 3 or above radioactive pneumonia; 7.Grade 2 or above immune-related side effects have occurred in the past; 8.Imaging revealed significant pulmonary interstitial changes; 9.Active infectious diseases (e.g., hepatitis (except carriers), tuberculosis, etc.); 10.Unable to take oral drugs or intolerant to oral probiotics;11.Poor complianceand inability to complete the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Duration of remission; | — |
Countries
China
Contacts
Public ContactZhu Jiang
Outcome results
None listed